Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226269 | 0.93 | MAPT (0.43) | MAPTTDP1LMNACES2CES1 | |
| SCHEMBL29384 | 0.89 | USP2 (0.52) | MAPTLMNACES2CES1ALDH1A1 | |
| Bicarbonate SCHEMBL31648960 | 0.88 | USP2 (0.51) | MAPTLMNACES2CES1ALDH1A1 | |
| Bicarbonate SCHEMBL1969232 | 0.88 | USP2 (0.51) | MAPTLMNACES2CES1ALDH1A1 | |
| Methoxymethane SCHEMBL28122245 | 0.88 | USP2 (0.51) | MAPTLMNACES2CES1ALDH1A1 | |
| Benzene SCHEMBL28180511 | 0.87 | USP2 (0.50) | MAPTLMNACES2CES1ALDH1A1 | |
| Acetic Acid SCHEMBL8064561 | 0.87 | USP2 (0.50) | MAPTLMNACES2CES1ALDH1A1 | |
| SCHEMBL17785925 | 0.86 | LMNA (0.46) | MAPTLMNACES2CES1ALDH1A1 | |
| SCHEMBL31250051 | 0.86 | LMNA (0.46) | MAPTLMNACES2CES1ALDH1A1 | |
| SCHEMBL28154355 | 0.86 | MAPT (0.42) | MAPTTDP1LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| EP-0550006-B1 | Use of N-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells | LIFEGROUP SPA (IT) | 1999-09-08 | — | — | EP | claimed |
| EP-0570714-B1 | Use of aminoalcohol-N-acylderivatives for the manufacture of a medicament for the treatment of neurogenic endoneural oedema of the peripheral nerve | LIFEGROUP SPA (IT) | 1999-09-01 | — | — | EP | claimed |
| EP-0804179-B1 | USE OF N-ACYL DERIVATIVES OF AMINOALCOHOLS IN THE MANUFACTURE OF A MEDICAMENT FOR PRACTISING NEUROPROTECTIVE ACTION IN NEUROPATHOLOGICAL STATES CONNECTED WITH EXCITOTOXICITY | LIFEGROUP SPA (IT) | 1999-07-14 | — | — | EP | claimed |
| EP-0751947-B1 | GLUCOSIDIC DERIVATIVES OF N-ACYL ALKYLAMINES EXERTING NEUROPROTECTIVE, NEUROTROPHIC AND ANTI-INFLAMMATORY ACTION, USEFUL IN ACUTE AND CHRONIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM CONNECTED WITH EXCITOTOXICITY | LIFEGROUP SPA (IT) | 1998-08-12 | — | — | EP | claimed |
| EP-0804179-A2 | USE OF N-ACYL DERIVATIVES OF AMINOALCOHOLS IN THE MANUFACTURE OF A MEDICAMENT FOR PRACTISING NEUROPROTECTIVE ACTION IN NEUROPATHOLOGICAL STATES CONNECTED WITH EXCITOTOXICITY | LIFEGROUP S.p.A. (IT) | 1997-11-05 | — | — | EP | claimed |
| US-5679667-A | Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve | LIFEGROUP S.P.A. (IT) | 1997-10-21 | — | — | US | claimed |
| EP-0751947-A1 | GLUCOSIDIC DERIVATIVES OF N-ACYL ALKYLAMINES EXERTING NEUROPROTECTIVE, NEUROTROPHIC AND ANTI-INFLAMMATORY ACTION, USEFUL IN ACUTE AND CHRONIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM CONNECTED WITH EXCITOTOXICITY | LIFEGROUP S.p.A. (IT) | 1997-01-08 | — | — | EP | claimed |
| US-5506224-A | ADMINISTERING TO TREAT MAMMALIAN PATHOLOGIES INVOLVING MAST CELL DEGRANULATION AS CONSEQUENCE OF NEUROGENIC AND/OR IMMUNOGENIC HYPERSTIMULATION | LIFEGROUP S.P.A. (IT) | 1996-04-09 | — | — | US | claimed |
| WO-1995025736-A1 | GLUCOSIDIC DERIVATIVES OF N-ACYL ALKYLAMINES EXERTING NEUROPROTECTIVE, NEUROTROPHIC AND ANTI-INFLAMMATORY ACTION, USEFUL IN ACUTE AND CHRONIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM CONNECTED WITH EXCITOTOXICITY | LIFEGROUP S.P.A. (IT) | 1995-09-28 | — | — | WO | claimed |
| WO-1995025509-A2 | USE OF N-ACYL DERIVATIVES OF AMINOALCOHOLS IN THE MANUFACTURE OF A MEDICAMENT FOR PRACTISING NEUROPROTECTIVE ACTION IN NEUROPATHOLOGICAL STATES CONNECTED WITH EXCITOTOXICITY | LIFEGROUP S.P.A. (IT) | 1995-09-28 | — | — | WO | claimed |
| EP-0550006-A2 | Use of N-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells | LIFEGROUP S.p.A. (IT) | 1993-07-07 | — | — | EP | claimed |
| EP-0072286-B2 | ORGANIC AMIDE COMPOUNDS DERIVED FROM NITROGENOUS LIPIDS | FIDIA S.p.A. (IT) | 1992-12-09 | — | — | EP | claimed |
| EP-0072286-B1 | ORGANIC AMIDE COMPOUNDS DERIVED FROM NITROGENOUS LIPIDS | FIDIA S.p.A. (IT) | 1986-10-29 | — | — | EP | claimed |
| EP-0072286-A1 | Organic amide compounds derived from nitrogenous lipids | FIDIA S.p.A. (IT) | 1983-02-16 | — | — | EP | claimed |
| EP-3562830-B1 | HYDROXYBENZOIC ACID DERIVATIVES, METHODS AND USES THEREOF | UNIV DO PORTO (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11078222-B2 | Hydroxybenzoic acid derivatives, methods and uses thereof | UNIVERSIDADE DO PORTO (PT) | 2021-08-03 | — | — | US | disclosed |
| EP-0072286-B1 | ORGANIC AMIDE COMPOUNDS DERIVED FROM NITROGENOUS LIPIDS | FIDIA S.p.A. (IT) | 1986-10-29 | — | — | EP | disclosed |
| EP-0072286-A1 | Organic amide compounds derived from nitrogenous lipids | FIDIA S.p.A. (IT) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078222-B2 | Hydroxybenzoic acid derivatives, methods and uses thereof | HAGH, HOGA1, NDUFAB1 | MAPT 2714/4885TDP1 422/4885LMNA 1679/4885 |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | MAPT 1479/4885TDP1 2814/4885LMNA 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.